BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 11408532)

  • 1. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
    Traynor JR; Nahorski SR
    Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
    Chen F; Lawrence AJ
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor.
    Alt A; Mansour A; Akil H; Medzihradsky F; Traynor JR; Woods JH
    J Pharmacol Exp Ther; 1998 Jul; 286(1):282-8. PubMed ID: 9655870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
    Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
    Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ; Traynor JR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
    Szekeres PG; Traynor JR
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
    J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.
    Vogt LJ; Sim-Selley LJ; Childers SR; Wiley RG; Vogt BA
    J Pharmacol Exp Ther; 2001 Dec; 299(3):840-8. PubMed ID: 11714867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic ethanol and withdrawal on the mu-opioid receptor- and 5-Hydroxytryptamine(1A) receptor-stimulated binding of [(35)S]Guanosine-5'-O-(3-thio)triphosphate in the fawn-hooded rat brain: A quantitative autoradiography study.
    Chen F; Lawrence AJ
    J Pharmacol Exp Ther; 2000 Apr; 293(1):159-65. PubMed ID: 10734165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
    Breivogel CS; Selley DE; Childers SR
    J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic ethanol consumption reduces delta-and mu-opioid receptor-stimulated G-protein coupling in rat brain.
    Saland LC; Abeyta A; Frausto S; Raymond-Stintz M; Hastings CM; Carta M; Valenzuela CF; Savage DD
    Alcohol Clin Exp Res; 2004 Jan; 28(1):98-104. PubMed ID: 14745307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration.
    Maher CE; Martin TJ; Childers SR
    Life Sci; 2005 Jul; 77(10):1140-54. PubMed ID: 15890372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
    Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
    Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.
    Kersanté F; Moulédous L; Zajac JM; Mollereau C
    Neurochem Int; 2010; 56(6-7):768-73. PubMed ID: 20211672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.